Pharmacokinetic and Exploratory Exposure–response Analysis of Pertuzumab in Patients With Operable HER2-positive Early Breast Cancer in the APHINITY Study
Cancer Chemotherapy and Pharmacology - Germany
doi 10.1007/s00280-019-03826-1
Full Text
Open PDFAbstract
Available in full text
Date
April 11, 2019
Authors
Publisher
Springer Science and Business Media LLC